Abstract: The present invention relates to a metal oxide-platinum compound catalyst comprising 5 to 95 parts by weight of a metal oxide and 95 to 5 parts by weight of platinum as the balance. The platinum has a form to reticulately cover at least a part of a particle of the metal oxide. The wires constituting the platinum mesh have an average wire diameter of 5 nm or smaller.

Abstract: The present invention relates to a metal oxide-platinum compound catalyst comprising 5 to 95 parts by weight of a metal oxide and 95 to 5 parts by weight of platinum as the balance. The platinum has a form to reticulately cover at least a part of a particle of the metal oxide. The wires constituting the platinum mesh have an average wire diameter of 5 nm or smaller.

Abstract: A process of manufacturing inorganic nanofibers, without using an organic polymer, using a highly reactive metal alkoxide such as titanium alkoxide or zirconium alkoxide, in particular, a process in which inorganic nanofibers can be stably produced over a long period, is provided. It is a process of manufacturing inorganic nanofibers by electrospinning using a sol solution containing an inorganic component as a main component, characterized in that the sol solution contains a metal alkoxide having a high reactivity and a salt catalyst, and that the salt catalyst is an amine compound having an N—N bond, an N—O bond, an N—C?N bond, or an N—C?S bond.

Abstract: To provide a pharmaceutical composition which can enhance the storage stability of 1-(1-hydroxymethyl-2,3-dihydroxypropyloxymethyl)-2-nitroimidazole without impairing the effect of the compound. The pharmaceutical composition includes 1-(1-hydroxymethyl-2,3-dihydroxypropyloxymethyl)-2-nitroimidazole, which is represented by formula (1): and a compound having chelating ability.

Abstract: Disclosed are: a polyorganosiloxane composition which can be cured into a product having high strength and has little influence on the environment; and a cured product of the polyorganosiloxane composition. Specifically disclosed are: a polyorganosiloxane composition comprising (A) a polyorganosiloxane in which at least one end in the molecule is modified with a silanol, (B) a titanium alkoxide in an amount of 0.01 to 2 moles relative to 1 mole of the polyorganosiloxane, and (C) an ?-hydroxycarbonyl compound or a hydroxycarboxylic acid ester in an amount of 0.01 to 2 moles relative to 1 mole of the polyorganosiloxane; and a cured product of the polyorganosiloxane composition.

Abstract: To provide a pharmaceutical composition which can enhance the storage stability of 1-(1-hydroxymethyl-2,3-dihydroxypropyloxymethyl)-2-nitroimidazole without impairing the effect of the compound. The pharmaceutical composition includes 1-(1-hydroxymethyl-2,3-dihydroxypropyloxymethyl)-2-nitroimidazole, which is represented by formula (1): and a compound having chelating ability.

Abstract: Disclosed is an organosiloxane composition which can be produced at low cost and is usable for bonding of glasses, metals and resins. The organosiloxane composition can provide a cured product exhibiting excellent heat resistance and cold resistance, while having high strength and high transparency. Specifically disclosed is a polyorganosiloxane composition containing (A) a polyorganosiloxane wherein at least one end of each molecule is modified with a silanol group, and (B) 0.5-4.0 moles of a metal alkoxide per 1 mole of the polyorganosiloxane, wherein the mean molecular weight (Mw) of the polyorganosiloxane according to the mass fraction is not more than 1,000. Also specifically disclosed are a cured product of the composition and a method for producing the composition.

Abstract: To provide a pharmaceutical composition which can enhance the storage stability of 1-(1-hydroxymethyl-2,3-dihydroxypropyloxymethyl)-2-nitroimidazole without impairing the effect of the compound. The pharmaceutical composition includes 1-(1-hydroxymethyl-2,3-dihydroxypropyloxymethyl)-2-nitroimidazole, which is represented by formula (1): and a compound having chelating ability.

Abstract: A lens-interchangeable camera includes a focus detector performing focus detection and a controller performing a drive control of a lens based on a defocus amount. The controller finishes focusing operation without driving the lens when the defocus amount is out a range of a first in-focus determination width, and performs the focusing operation when the defocus amount is out a range of the first in-focus determination width. The controller finishes the focusing operation without performing the focus detection again after completing the drive when the defocus amount is out a range of a second in-focus determination width, and performs the focus detection again after completing the drive when the defocus amount is out a range of the second in-focus determination width. The second in-focus determination width is set to be greater than the first in-focus determination width and be greater than or equal to a drive limit value.

Abstract: To provide a pharmaceutical composition containing a 2-nitroimidazole derivative, which has high solubility in an aqueous carrier and high stability. The pharmaceutical composition is characterized by containing 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole and creatinine, and containing creatinine of 0.001 to 1 part by mass with respect to 1 part by mass of 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole.

Abstract: A Cancer radiotherapeutic method using 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole (compound (i), and creatinine in an amount of 0.001 to part by mass with respect to 1 part by mass of compound (1); and irradiation.

Abstract: To provide a pharmaceutical composition containing a 2-nitroimidazole derivative, which has high solubility in an aqueous carrier and high stability. The pharmaceutical composition is characterized by containing 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole and creatinine, and containing creatinine of 0.001 to 1 part by mass with respect to 1 part by mass of 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole.

Abstract: To provide a pharmaceutical composition containing a 2-nitroimidazole derivative, which has high solubility in an aqueous carrier and high stability. The pharmaceutical composition is characterized by containing 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole and creatinine, and containing creatinine of 0.001 to 1 part by mass with respect to 1 part by mass of 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole.

Abstract: To provide a pharmaceutical composition containing a 2-nitroimidazole derivative, which has high solubility in an aqueous carrier and high stability. The pharmaceutical composition is characterized by containing 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole and creatinine, and containing creatinine of 0.001 to 1 part by mass with respect to 1 part by mass of 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole.

Abstract: To provide a pharmaceutical composition which can enhance the storage stability of 1-(1-hydroxymethyl-2,3-dihydroxypropyloxymethyl)-2-nitroimidazole without impairing the effect of the compound. The pharmaceutical composition includes 1-(1-hydroxymethyl-2,3-dihydroxypropyloxymethyl)-2-nitroimidazole, which is represented by formula (1): and a compound having chelating ability.

Abstract: To provide a pharmaceutical composition which can enhance the storage stability of 1-(1-hydroxymethyl-2,3-dihydroxypropyloxymethyl)-2-nitroimidazole without impairing the effect of the compound. The pharmaceutical composition includes 1-(1-hydroxymethyl-2,3-dihydroxypropyloxymethyl)-2-nitroimidazole, which is represented by formula (1): and a compound having chelating ability.

Abstract: A lens-interchangeable camera includes a focus detector performing focus detection and a controller performing a drive control of a lens based on a defocus amount. The controller finishes focusing operation without driving the lens when the defocus amount is out a range of a first in-focus determination width, and performs the focusing operation when the defocus amount is out a range of the first in-focus determination width. The controller finishes the focusing operation without performing the focus detection again after completing the drive when the defocus amount is out a range of a second in-focus determination width, and performs the focus detection again after completing the drive when the defocus amount is out a range of the second in-focus determination width. The second in-focus determination width is set to be greater than the first in-focus determination width and be greater than or equal to a drive limit value.

Abstract: Disclosed is an organosiloxane composition which can be produced at low cost and is usable for bonding of glasses, metals and resins. The organosiloxane composition can provide a cured product exhibiting excellent heat resistance and cold resistance, while having high strength and high transparency. Specifically disclosed is a polyorganosiloxane composition containing (A) a polyorganosiloxane wherein at least one end of each molecule is modified with a silanol group, and (B) 0.5-4.0 moles of a metal alkoxide per 1 mole of the polyorganosiloxane, wherein the mean molecular weight (Mw) of the polyorganosiloxane according to the mass fraction is not more than 1,000. Also specifically disclosed are a cured product of the composition and a method for producing the composition.

Abstract: There is provided a method for starting a spark ignition engine having multiple cylinders. The method may comprise supplying air and fuel for restart into a first cylinder before said engine completely stops, and igniting the mixture of said air and said fuel in said first cylinder in response to an engine restart request, wherein said first cylinder is on an expansion stroke when said engine stops. The method may also include, after said piston in said first cylinder starts moving, injecting fuel into a second cylinder that is on a compression stroke when said engine stops, on a compression stroke where a piston of said second cylinder is moving in a direction opposite to an operative direction of said piston in said first cylinder.

Abstract: Disclosed are: a polyorganosiloxane composition which can be cured into a product having high strength and has little influence on the environment; and a cured product of the polyorganosiloxane composition. Specifically disclosed are: a polyorganosiloxane composition comprising (A) a polyorganosiloxane in which at least one end in the molecule is modified with a silanol, (B) a titanium alkoxide in an amount of 0.01 to 2 moles relative to 1 mole of the polyorganosiloxane, and (C) an ?-hydroxycarbonyl compound or a hydroxycarboxylic acid ester in an amount of 0.01 to 2 moles relative to 1 mole of the polyorganosiloxane; and a cured product of the polyorganosiloxane composition.